Table 3.
Point Estimates and 95% Confidence Intervals for Patients With Model Convergence as Calculated by the Method of Neumann et al
| IDa | Treatment | V0b | t0c | cd | ε e | δ f | λ 1 g | λ 2 h |
|---|---|---|---|---|---|---|---|---|
| 013698D | S | 7.30 (6.87–7.5) |
9.00 (8.30–9.02) |
47.77 (41.54–49.0) |
.76 (.15–.94) |
.44 (.04–2.59) |
47.88 (41.84–49.76) |
.33 (.029–.50) |
| 013703J | P | 6.86 (.73–7.34) |
12.04 (2.00–14.99) |
3.93 (2.33–37.14) |
.93 (.78–.98) |
.11 (.02–.25) |
3.94 (2.32–37.18) |
.10 (.019–.20) |
| 013713I | S | 6.92 (6.74–7.26) |
11.39 (2–13.70) |
22.67 (1.47–240) |
.55 (.071–.89) |
.21 (.007–19.20) |
22.76 (1.77–240.23) |
.12 (0–.16) |
| 044516L | S | 6.60 (5.95–6.76) |
7.64 (2.96–12.00) |
100.76 (0–240) |
0 (0–.74) |
19.20 (.08–19.20) |
119.96 (19.20–259.2) |
0 (0–.14) |
| 044519F | S | 7.47 (6.97–7.50) |
6.45 (2.00–13.99) |
9.48 (3.99–48.45) |
.99 (.98–.997) |
.25 (.07–.35) |
9.49 (3.99–48.45) |
.25 (.075–.34) |
| 242425D | P | 6.74 (6.56–6.81) |
2.00 (2.00–13.71) |
2.19 (1.81–4.43) |
.86 (.76–.89) |
.036 (.009–.07) |
2.20 (1.81–4.44) |
.031 (.008–.53) |
| 243265C | S | 5.58 (5.47–5.74) |
11.66 (2.00–14.01) |
28.65 (1.97–240) |
.76 (.36–.88) |
.082 (.010–.37) |
28.67 (1.98–240.23) |
.062 (.008–.14) |
| 240108G | P | 5.14 (3.96–6.32) |
2.00 (2.00–2.00) |
5.76 (0–13.1) |
.997 (.98–1) |
N/A | 5.74 (0–13.0) |
N/A |
| C02 | P | 5.80 (5.13–5.87) |
7.33 (4.05–12.38) |
112.9 (12.78–240) |
0 (0–.61) |
19.20 (.01–19.20) |
132.10 (18.41–259.20) |
0 (0–.091) |
| C03 | S | 5.27 (4.99–5.78) |
12.24 (2–14.17) |
36.26 (2.06–138.70) |
.81 (0–.97) |
.096 (.0084–19.20) |
36.28 (2.07–138.78) |
.078 (0–.14) |
| C05 | S | 6.39 (5.96–6.94) |
10.95 (2.00–13.57) |
31.61 (2.31–142.37) |
.90 (.67–.99) |
.21 (.022–.42) |
31.63 (2.35–142.39) |
.19 (.022–.31) |
| C06 | P | 5.88 (5.77–5.96) |
7.85 (6.20–12.45) |
98.96 (29.71–196.05) |
.10 (0–.33) |
.10 (.004–19.20) |
99.06 (29.74–201.20) |
.011 (0–.032) |
| C07 | S | 5.90 (5.57–6.36) |
11.36 (2.00–14.79) |
33.20 (3.94–47.67) |
.98 (.94–.997) |
.19 (.018–.29) |
33.20 (3.94–47.67) |
.18 (.018–.28) |
| C08 | S | 5.82 (5.74–5.94) |
11.26 (3.87–13.03) |
29.49 (1.98–71.12) |
.53 (.36–.68) |
.043 (.0017–.15) |
29.50 (1.99–71.18) |
.023 (.0011–.058) |
| C09 | P | 5.65 (5.56–5.71) |
5.97 (2.00–7.65) |
163.60 (99.03–240) |
0 (0–.20) |
19.20 (.0084–19.20) |
182.80 (103.28–257.73) |
0 (0–.022) |
| C10 | P | 6.67 (6.63–6.78) |
9.84 (2–10.81) |
14.84 (0.94–194.23) |
.51 (.34–.67) |
.032 (.012–.071) |
14.86 (.95–194.31) |
.016 (.0075–.024) |
| C11 | P | 4.96 (4.85–5.04) |
11.96 (7.17–13.33) |
4.39 (3.06–5.64) |
.99 (.98–.994) |
.066 (.0043–.097) |
4.39 (3.06–5.64) |
.065 (.0043–.095) |
| C12 | S | 6.59 (6.39–7.25) |
9.38 (2.00–10.53) |
38.79 (2.85–132.18) |
.94 (.87–.99) |
.18 (.037–.27) |
38.80 (2.86–132.19) |
.017 (.036–.24) |
| C15 | P | 7.03 (6.90–7.36) |
12.01 (8.32–14.40) |
9.26 (3.72–61.24) |
.93 (.87–.97) |
.056 (.0051–.14) |
9.27 (3.73–61.24) |
9.052 (.0048–.13) |
NOTE. The 95% confidence interval, calculated from a bootstrap with 199 repetitions, is shown in parentheses below the fitted point estimate.
S, standard IFN alfa2a + ribavirin; P, PEG-IFN alfa2a + ribavirin; N/A, not applicable.
Data from Neumann et al.3
HCV/HIV-co-infected patients are listed first with 6 digits and a letter. HCV-monoinfected controls are identified by “C” + 2 digits.
Viral load (log IU/mL) at time t0.
Delay (hours) between start of treatment and onset of action.
Clearance rate of free virus (per day).
Percent (%) efficacy of treatment at blocking viral production.
Death rate of infected hepatocytes (per day); not applicable for 240108G owing to rapid clearance (<1day).
Slope of first phase decline per day (log scale), calculated through first 60 hours of viral load measurements.
Slope of second phase decline per day (log scale), calculated through first 400 hours of viral load measurements with the exception of C03 and C10. These patients had significant improvement of model fit with utilization of viral load measurements taken at days 28 and 56, and this information is included in the second-phase parameter estimates. Not applicable for 240108G owing to rapid clearance (<1 day).